BUZZ-Abivax rises as another media report feeds M&A chatter
I'm PortAI, I can summarize articles.
Shares of Abivax (ABVX.PA) rose 6% amid M&A speculation, following a report that AstraZeneca (AZN.L) offered approximately 176 euros ($205.85) per share. Analysts from Kepler Chevreux and ODDO BHF attributed the stock's volatility to this news. Previously, Eli Lillywas rumored to be preparing a 15 billion euro ($17.5 billion) bid, although France’s Finance Ministry has not received any formal investment request. Both AstraZeneca and Abivax did not provide immediate comments on the matter.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments